<DOC>
	<DOCNO>NCT01319994</DOCNO>
	<brief_summary>According current estimate , nearly 1 % general population treat long-term glucocorticoid . Chronic hypercortisolism lead phenotype resembles metabolic syndrome . The investigator show inhibition adenosine-monophosphate-activated protein kinase ( AMPK ) activity adipose tissue play role corticosteroid-mediated insulin resistance . Metformin , one mainstay therapy type 2 diabetes , know activator AMPK , mediate beneficial effect glucose lipid metabolism . The investigator show animal model metformin - via alter AMPK activity - prevents development metabolic complication glucocorticoid excess , investigator wish confirm human study . The aim prospective , randomised , double-blind , placebo-controlled study investigate effect metformin treatment metabolic parameter patient long-term high-dose glucocorticoid . The study part investigator translational project could rapidly lead immediate patient benefit , improve quality life reduce health care cost NHS .</brief_summary>
	<brief_title>Prevention Metabolic Complications Glucocorticoid Excess</brief_title>
	<detailed_description>2 Study Aims Objectives To investigate effect metformin treatment metabolic parameter patient long-term high dose GCs . 3 Study Design 3.1 General Design We recruit patient ( 18-75y ) excess glucocorticoid either Cushing 's syndrome inflammatory condition require GC treatment ( e.g . rheumatoid arthritis , giant cell arteritis/polymyalgia rheumatica ) pilot , randomise , double-blind , placebo-controlled trial . These patient treat metformin prevent reverse metabolic complication . Prevention algorithm : Patients start GC treatment predictably ≥12w ≥10mg/d prednisolone ( equivalent ) dose consent participate study randomly assign receive either placebo ( 20 patients/group , see power calculation ) metformin maximum tolerate dose minimum 850 mg bd 12w . Treatment algorithm : Consenting patient already long-term GC treatment ( ≥4w , ≥20mg/d ) expect continue least 12w ≥10mg/d prednisolone randomly assign receive either placebo metformin 12w . In algorithm , metformin treatment start gradually ( standard practice ) avoid gastrointestinal side effect full dose reach day 10 . Patients full clinical assessment start metformin treatment end 12w treatment period . Anthropometric biochemical parameter questionnaire repeat 4 8 week . Patients endogenous Cushing 's syndrome randomly assign receive either placebo ( 10 patients/group ) metformin maximum tolerate dose minimum 850 mg bd 4 week . Patients full clinical assessment start metformin treatment end 4w treatment period .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>patient diagnose rheumatological disease start yet GC treatment • Rheumatology patient treat GC &gt; 20mg/d least 4wks minimal duration prospective therapy 12w dose prednisolone ≥10mg/d ( equivalent GC ) ambulatory patient patient &gt; 18 year old ability understand verbal write instruction inform consent prior therapy metformin last 6 month preexist diabetes pregnancy breastfeed liver impairment : ALT and/or AST ≥2.5 x UNL renal impairment : serum creatinine level ≥135.0 µmol/L male ≥110.0 µmol/L female current malignancy patient unable give write informed consent patient understand English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>glucocorticoid</keyword>
</DOC>